By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


SEARCH JOBS








Company News
First U.S. Patients Enroll In Boehringer Ingelheim's Global RE-DUAL PCI And RE-CIRCUIT Trials Evaluating Pradaxa (Dabigatran Etexilate Mesylate) 7/30/2015 10:29:11 AM
Boehringer Ingelheim Enters Into An Exclusive License Agreement With Hanmi Pharma To Develop 3rd Generation EGFR Targeted Therapy In Lung Cancer 7/28/2015 11:07:15 AM
Boehringer Ingelheim Enters Into An Exclusive License Agreement With Hanmi Pharma To Develop 3rd Generation EGFR Targeted Therapy In Lung Cancer 7/28/2015 10:51:10 AM
Hikma (HIK.L) Snags Boehringer Ingelheim's U.S. Generics Biz for $2.65 Billion 7/28/2015 5:46:08 AM
Embattled Vitae Pharma (VTAE) and Boehringer Ingelheim Relationship Takes Another Blow, Drops BACE Inhibitor Program for Alzheimer’s 7/27/2015 6:03:57 AM
Boehringer Ingelheim Release: MHRA Review Confirms Benefit/Risk Profile Of Alteplase - The Only Licensed Clot Buster For Acute Ischaemic Stroke 7/24/2015 10:51:21 AM
Boehringer Ingelheim To Sponsor American College of Cardiology-Led Diabetes Collaborative Registry 7/22/2015 2:38:04 PM
Boehringer Ingelheim Welcomes The Inclusion Of OFEV (Nintedanib*) In The Updated International Treatment Guidelines For Idiopathic Pulmonary Fibrosis (IPF) 7/15/2015 9:33:25 AM
Boehringer Ingelheim Release: Phase III Data Published In The Lancet Oncology Shows A Significant Overall Survival Benefit Of Giotrif (Afatinib) Compared To Tarceva(Erlotinib) 7/6/2015 11:14:22 AM
Boehringer Ingelheim Release: New Advance In COPD Maintenance Treatment, Spiolto Respimat, Approved In First European Countries 7/2/2015 9:42:04 AM
12345678910...
//-->